The number of drug resistant cases of gonorrhea have increased in the U.S. in recent years, according to a new study from researchers at the Centers for Disease Control and Prevention. The agency released an official statement earlier this week noting that "the future of current treatment options may be in jeopardy."
French nanomedicine company Nanobiotix SA (NANO.PA) has reported successful results from its phase I/II trial of its lead product, NBTXR3, in head and neck cancer.
The first ever Zika virus vaccine human trials will begin in the next few weeks, according to Inovio Pharmaceuticals, a company based in Plymouth Meeting, Pennsylvania. The vaccine, named GLS-5700, will initially be tested in 40 healthy human volunteers. Inovio worked on the vaccine with GeneOne Life Science, based in Seoul, South Korea.